Skip to main content
Erschienen in: Clinical Drug Investigation 6/2011

01.06.2011 | Original Research Article

Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically HIV-Infected Children, Adolescents and Young Adults

A 60-Month Follow-Up Study

verfasst von: Dr Alessandra Viganò, Giorgio Bedogni, Valeria Manfredini, Vania Giacomet, Chiara Cerini, Francesca di Nello, Francesca Penagini, Cristiana Caprio, Gian Vincenzo Zuccotti

Erschienen in: Clinical Drug Investigation | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective: Sporadic cases of renal toxicity have been reported in HIV-infected children treated with tenofovir disoproxil fumarate (TDF). We assessed the long-term renal safety of TDF in a cohort of vertically HIV-infected children, adolescents and young adults.
Methods: We evaluated 26 HIV-infected children, adolescents and young adults, aged 4.9–17.4 years at baseline, every 6 months for 60 consecutive months. At the baseline visit, they had an undetectable viral load and a good immune reconstitution and were being treated with lamivudine, stavudine and a protease inhibitor (PI). At the same visit, stavudine was replaced with TDF and the PI with efavirenz. Serum creatinine, estimated glomerular filtration rate (GFR), urine protein to creatinine ratio, serum phosphate, ratio of the maximum rate of tubular phosphate reabsorption to the GFR (TmPO4/GFR), urine glucose, and urine α1-microglobulin to creatinine ratio were used as markers of renal function. The outcome-time relationships were studied using generalized estimating equations (GEEs). In addition to time (continuous, ten equally spaced intervals), sex, age at baseline and CD4+ T-cell count were used as covariates.
Results: A moderate reduction in GFR was observed only once in an underweight female patient. There was no occurrence of proteinuria, hypophosphataemia or glycosuria. Moreover, TmPO4/GFR was stable and the urine α1-microglobulin to creatinine ratio was always within normal limits.
Conclusion: TDF had an excellent renal safety profile in HIV-infected children, adolescents and young adults regularly followed up for 60 months.
Literatur
1.
Zurück zum Zitat Boyd MA. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS 2009 May; 4(3): 194–9PubMedCrossRef Boyd MA. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS 2009 May; 4(3): 194–9PubMedCrossRef
2.
Zurück zum Zitat Atta MG, Deray G, Lucas GM. Antiretroviral nephro-toxicities. Semin Nephrol 2008 Nov; 28(6): 563–75PubMedCrossRef Atta MG, Deray G, Lucas GM. Antiretroviral nephro-toxicities. Semin Nephrol 2008 Nov; 28(6): 563–75PubMedCrossRef
3.
Zurück zum Zitat Rodriguez-Nóvoa S, Alvarez E, Labarga P, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010 Jul; 9(4): 545–59PubMedCrossRef Rodriguez-Nóvoa S, Alvarez E, Labarga P, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010 Jul; 9(4): 545–59PubMedCrossRef
4.
Zurück zum Zitat Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010 Sep 1; 51(5): 496–505PubMedCrossRef Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010 Sep 1; 51(5): 496–505PubMedCrossRef
5.
Zurück zum Zitat Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004 May; 48(5): 1469–87PubMedCrossRef Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004 May; 48(5): 1469–87PubMedCrossRef
6.
Zurück zum Zitat Peyrière H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35(3): 269–73PubMedCrossRef Peyrière H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35(3): 269–73PubMedCrossRef
7.
Zurück zum Zitat Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18(7): 1074–6PubMedCrossRef Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18(7): 1074–6PubMedCrossRef
8.
Zurück zum Zitat Parsonage MJ, Wilkins EG, Snowden N, et al. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6(5): 341–6PubMedCrossRef Parsonage MJ, Wilkins EG, Snowden N, et al. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6(5): 341–6PubMedCrossRef
9.
Zurück zum Zitat Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatmentnaive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47(1): 74–8PubMedCrossRef Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatmentnaive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47(1): 74–8PubMedCrossRef
10.
Zurück zum Zitat Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292(2): 191–201PubMedCrossRef Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292(2): 191–201PubMedCrossRef
11.
Zurück zum Zitat Shooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002, Jun 14; 16(9): 1257–63CrossRef Shooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002, Jun 14; 16(9): 1257–63CrossRef
12.
Zurück zum Zitat Moyle GJ, Sabin CA, Cartledge J, et al., RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20(16): 2043–50PubMedCrossRef Moyle GJ, Sabin CA, Cartledge J, et al., RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20(16): 2043–50PubMedCrossRef
13.
Zurück zum Zitat Martínez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009; 51(3): 290–7PubMedCrossRef Martínez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009; 51(3): 290–7PubMedCrossRef
14.
Zurück zum Zitat Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005 Dec; 116(6): e846–54PubMedCrossRef Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005 Dec; 116(6): e846–54PubMedCrossRef
15.
Zurück zum Zitat Viganò A, Zuccotti GV, Martelli L, et al. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig 2007; 27(8): 573–81PubMedCrossRef Viganò A, Zuccotti GV, Martelli L, et al. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig 2007; 27(8): 573–81PubMedCrossRef
16.
Zurück zum Zitat Soler-Palacín P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS 2011; 25(2): 171–6PubMedCrossRef Soler-Palacín P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS 2011; 25(2): 171–6PubMedCrossRef
17.
Zurück zum Zitat Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (6–20 y). Eur J Clin Nutr 2002 Feb; 56(2): 171–80PubMedCrossRef Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (6–20 y). Eur J Clin Nutr 2002 Feb; 56(2): 171–80PubMedCrossRef
18.
Zurück zum Zitat Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviralnaive HIV-1-infected patients: data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005 Apr; 20(4): 743–6PubMedCrossRef Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviralnaive HIV-1-infected patients: data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005 Apr; 20(4): 743–6PubMedCrossRef
19.
Zurück zum Zitat Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003 Jun; 111 (6 Pt 1): 1416–21PubMedCrossRef Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003 Jun; 111 (6 Pt 1): 1416–21PubMedCrossRef
20.
Zurück zum Zitat Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009 Mar; 20(3): 629–37PubMedCrossRef Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009 Mar; 20(3): 629–37PubMedCrossRef
21.
Zurück zum Zitat Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda (MD): NIH, 2005 Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda (MD): NIH, 2005
22.
Zurück zum Zitat Alon U, Hellerstein S. Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr Nephrol 1994 Apr; 8(2): 250–1PubMedCrossRef Alon U, Hellerstein S. Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr Nephrol 1994 Apr; 8(2): 250–1PubMedCrossRef
23.
Zurück zum Zitat Hardin JW, Hilbe J. Generalized estimating equations. Boca Raton (FL): Chapman & Hall, 2003 Hardin JW, Hilbe J. Generalized estimating equations. Boca Raton (FL): Chapman & Hall, 2003
24.
Zurück zum Zitat Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. Chichester: John Wiley, 2008 Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. Chichester: John Wiley, 2008
25.
Zurück zum Zitat Viganò A, Brambilla P, Pattarino G, et al. Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study. Clin Drug Investig 2009; 29(2): 101–9PubMedCrossRef Viganò A, Brambilla P, Pattarino G, et al. Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study. Clin Drug Investig 2009; 29(2): 101–9PubMedCrossRef
26.
Zurück zum Zitat Kruse K, Kracht U, Göpfert G. Renal threshold phosphate concentration (TmPO4/GFR). Arch Dis Child 1982 Mar; 57(3): 217–23PubMedCrossRef Kruse K, Kracht U, Göpfert G. Renal threshold phosphate concentration (TmPO4/GFR). Arch Dis Child 1982 Mar; 57(3): 217–23PubMedCrossRef
27.
Zurück zum Zitat Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006 Jan 15; 42(2): 283–90PubMedCrossRef Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006 Jan 15; 42(2): 283–90PubMedCrossRef
28.
Zurück zum Zitat Hawkins S, Ball C. Adverse events experienced by three children taking tenofovir and didanosine in combination. HIV Med 2007 Sep; 8(6): 411PubMedCrossRef Hawkins S, Ball C. Adverse events experienced by three children taking tenofovir and didanosine in combination. HIV Med 2007 Sep; 8(6): 411PubMedCrossRef
29.
Zurück zum Zitat Hussain S, Khayat A, Tolaymat A, et al. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol 2006 Jul; 21(7): 1034–6PubMedCrossRef Hussain S, Khayat A, Tolaymat A, et al. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol 2006 Jul; 21(7): 1034–6PubMedCrossRef
30.
Zurück zum Zitat Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J 2009 Jul; 28(7): 619–25PubMedCrossRef Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J 2009 Jul; 28(7): 619–25PubMedCrossRef
31.
Zurück zum Zitat Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008 Oct 18; 22(16): 2155–63PubMedCrossRef Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008 Oct 18; 22(16): 2155–63PubMedCrossRef
32.
Zurück zum Zitat Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003 Sep 2; 139 (5 Pt 1): 313–20PubMed Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003 Sep 2; 139 (5 Pt 1): 313–20PubMed
33.
Zurück zum Zitat Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J 2009 Mar; 28(3): 204–9PubMedCrossRef Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J 2009 Mar; 28(3): 204–9PubMedCrossRef
34.
Zurück zum Zitat D’Amico G, Bazzi C. Urinary protein and enzyme excretion as markers of tubular damage. Curr Opin Nephrol Hypertens 2003 Nov; 12(6): 639–43PubMedCrossRef D’Amico G, Bazzi C. Urinary protein and enzyme excretion as markers of tubular damage. Curr Opin Nephrol Hypertens 2003 Nov; 12(6): 639–43PubMedCrossRef
35.
Zurück zum Zitat Papaleo A, Warszawski J, Salomon R, et al. Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. Pediatr Infect Dis J 2007 Oct; 26(10): 949–51PubMedCrossRef Papaleo A, Warszawski J, Salomon R, et al. Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. Pediatr Infect Dis J 2007 Oct; 26(10): 949–51PubMedCrossRef
36.
Zurück zum Zitat Davey PG, Gosling P. Beta 2-microglobulin instability in pathological urine. Clin Chem 1982 Jun; 28(6): 1330–3PubMed Davey PG, Gosling P. Beta 2-microglobulin instability in pathological urine. Clin Chem 1982 Jun; 28(6): 1330–3PubMed
37.
Zurück zum Zitat Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009 Mar 27; 23(6): 689–96PubMedCrossRef Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009 Mar 27; 23(6): 689–96PubMedCrossRef
38.
Zurück zum Zitat Judd A, Boyd KL, Stöhr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 2010 Feb 20; 24(4): 525–34PubMedCrossRef Judd A, Boyd KL, Stöhr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 2010 Feb 20; 24(4): 525–34PubMedCrossRef
39.
Zurück zum Zitat Guaraldi G, Roverato A, Giovanardi C, et al. Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study. J Antimicrob Chemother 2009 Feb; 63(2): 374–9PubMedCrossRef Guaraldi G, Roverato A, Giovanardi C, et al. Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study. J Antimicrob Chemother 2009 Feb; 63(2): 374–9PubMedCrossRef
40.
Zurück zum Zitat Reid A, Stöhr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008 Apr 15; 46(8): 1271–81PubMedCrossRef Reid A, Stöhr W, Walker AS, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008 Apr 15; 46(8): 1271–81PubMedCrossRef
Metadaten
Titel
Long-Term Renal Safety of Tenofovir Disoproxil Fumarate in Vertically HIV-Infected Children, Adolescents and Young Adults
A 60-Month Follow-Up Study
verfasst von
Dr Alessandra Viganò
Giorgio Bedogni
Valeria Manfredini
Vania Giacomet
Chiara Cerini
Francesca di Nello
Francesca Penagini
Cristiana Caprio
Gian Vincenzo Zuccotti
Publikationsdatum
01.06.2011
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 6/2011
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.2165/11590400-000000000-00000

Weitere Artikel der Ausgabe 6/2011

Clinical Drug Investigation 6/2011 Zur Ausgabe